Amphix Bio Secures Funding for Manufacturing Innovations
Amphix Bio, a pioneering company in regenerative medicine therapies, has recently announced the acquisition of a substantial $1M grant from the National Science Foundation (NSF). This funding is part of the Small Business Innovation Research (SBIR) Phase II program aimed at advancing manufacturing technologies for their innovative supramolecular peptide therapeutics. These therapeutics are designed to stimulate the patient's cellular activity, enabling the body to initiate its own regenerative processes.
Enhancements in Production Technologies
The investment from NSF will empower Amphix Bio to create an off-the-shelf implant tailored for spinal fusion surgeries. This novel product has received designation as a Breakthrough Device by the FDA, specifically targeting the management of back pain attributed to degenerative disc disease. Following the successful completion of the Phase I project, which focused on developing new production methods and formulating a moldable, putty-like composition effective in large animal studies, Amphix Bio is now poised to elevate its production capabilities.
Goals and Ambitions of the Phase II Project
In this next phase, the objectives include not only increasing the volume of the therapeutic peptides but also refining manufacturing methods for the putty formulation and conducting essential biocompatibility assessments. The culmination of these efforts will lead to the preparation of final-packaged, sterilized spinal implants, validated through rigorous testing in large animal models—this is a crucial step prior to the initiation of clinical trials.
Leadership and Team Expansion
Nick Sather, PhD, the co-founder and CEO of Amphix Bio, expressed gratitude for the NSF's investment. He emphasized the company’s commitment to advancing its manufacturing capabilities to transition the supramolecular therapeutics platform into real-world clinical applications. Dr. Sather highlighted the potential of their technology to provide simpler, safer alternatives to conventional treatments, minimizing the risks associated with procedures involving autograft tissue or recombinant proteins.
Strengthening the Team for Clinical Trials
To enhance operational effectiveness as they prepare for clinical trials, Amphix Bio has recently strengthened its team by onboarding several key individuals with extensive industry experience. Notably, Iwona Maciagiewicz, PhD, brings in-depth expertise in biotech manufacturing involving small molecules, biologics, and diagnostic innovations. Additionally, Hussain Sangji, PhD, who joined from Boston Consulting Group, offers a wealth of consulting experience in strategy and operations within the biopharma and MedTech sectors, further solidifying Amphix's capabilities.
Impact of Funding on Amphix Bio’s Research Initiatives
The NSF grant boosts Amphix Bio's total SBIR funding to $1.25M. Moreover, the company has recently secured non-dilutive funding from a local science and technology coalition, reinforcing its commitment to nurturing innovation. These financial resources will further enhance the company’s ongoing collaborations at prominent institutions, including Northwestern University. Notably, leading experts such as Wellington Hsu, MD, and Erin Hsu, PhD, from Northwestern's Feinberg School of Medicine, will play instrumental roles in overseeing pre-clinical testing and guiding the clinical development of the new therapy.
About Amphix Bio
Established in 2021, Amphix Bio emerged from Northwestern University and is headquartered in the Chicago area. The company is on a mission to introduce a groundbreaking class of supramolecular therapies, designed to instruct cells toward initiating regenerative responses and restoring functions compromised due to injury, disease, or aging. Their therapies leverage a multitude of biological signals to engage specific signaling pathways while providing scaffolding support for tissue regeneration. Ultimately, Amphix Bio aims to harness the potential of regenerative medicine to extend human healthspans, allowing individuals to lead longer, more productive lives.
Frequently Asked Questions
What is the primary focus of Amphix Bio?
Amphix Bio specializes in developing regenerative medicine therapies that promote the body’s own healing processes.
How much funding has Amphix Bio secured?
Amphix Bio has secured a total of $1.25M in SBIR funding from the NSF.
What are the expected outcomes of the Phase II project?
The goals include scaling up therapeutic peptide production and preparing for clinical trials by validating spinal implants.
Who leads the development efforts at Amphix Bio?
Nick Sather, PhD, serves as the CEO and co-founder, steering the company’s strategic initiatives.
Where was Amphix Bio founded?
Amphix Bio was founded in 2021 as a spinout from Northwestern University in Chicago.
